Gut Probiotic Study for Alzheimer’s-related Dementia and At-risk Adults
Official title: Probiotic Supplementation Safety and Feasibility Study in Preclinical Alzheimer's Disease
Run by University of Wisconsin, Madison · NCT07413744 · Data updated 2026-11-12
Researchers will test whether a probiotic supplement is safe and feasible for people with dementia or mild cognitive impairment due to Alzheimer’s, and for some with normal cognition but at risk, over up to a year.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | November 2026 |
| Main results expected | September 2029 |
| Study ends | September 2029 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT07413744 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 60+ with dementia or MCI due to Alzheimer's disease (biomarker-confirmed amyloid positivity) or cognitively unimpaired individuals enriched for amyloid positivity, recruited from Wisconsin clinics and community sources.
✕Probably not a fit
Individuals without the targeted amyloid positivity or with health conditions strongly affecting the gut microbiome may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase study enrolls 40 adults aged 60 and older, including 20 with dementia or MCI due to Alzheimer's and 20 with unimpaired cognition but enriched for amyloid positivity. Participants receive an oral probiotic or placebo for up to 12 months. The study will evaluate safety, feasibility of recruitment and follow-up, changes in gut microbiota, and gather preliminary data to inform a larger trial. Exploratory aims include potential mechanisms linking gut health to brain function, such as gut permeability and bile acid changes.
Why it matters
Potential benefit: If successful, the probiotic approach could be a safe, non-drug option to support gut-brain health in individuals affected by or at risk for Alzheimer's disease.
How similar studies have gone: Prior probiotic and gut-brain research in neurodegenerative contexts is exploratory but has shown signals in gut microbiota modulation and safety in older adults.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * MCI/AD or cognitively unimpaired, referred from a Wisconsin clinic that is part of the Wisconsin Alzheimer's Institute's (WAI) network, or recruited from the community. May have participated in: * Alzheimer's Disease Research Center (ADRC) clinical core study (2011-0030) * ADCP (26695, MCW IRB) * Synapse study (2018-1283) * ADRC Recruitment Registry (2016-0735) * At least 60 years of age or older * Good general health (other than cognitive impairment/dementia) with no conditions/medications affecting the gut microbiome (see exclusion criteria below) * Willing and able to comply with all study procedures for the duration of the study * Able to provide signed and dated informed consent form * Participant is not pregnant, lactating or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile) * Able to take oral medications * An informant to answer questionnaires about the participant Additional inclusion criteria for unimpaired participants: * Has MOCA score that falls within the range defined for cognitively healthy individuals Additional inclusion criteria for participants with MCI/AD * Abnormal cognitive function documented by neuropsychological testing * ADRC (2015-0030) Consensus Diagnosis Conference indicates dementia or MCI due to AD (for ADRC, ADCP, and Synapse participants only) * Meets NIA-AA criteria for MCI or AD. Exclusion Criteria: * Active or previous (within 6 months) participation in an Alzheimer's clinical intervention/trial (can be included if previously enrolled in placebo or control group) * Standard clinical care for dementia and medications used to treat MCI and Alzheimer's disease are acceptable, including monoclonal antibody therapy * Significant neurologic disease: Any significant neurologic disease, such as Parkinson's disease, stroke, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, subdural hematoma, multiple sclerosis, seizure disorder, or other significant deficits other than Alzheimer's or Mild Cognitive Impairment * Alcohol/substance: history of alcohol/substance dependence in the past year. * Significant medical illness: any significant systemic illness or unstable medical condition occurring during ADRC participation that could affect cognition (other than MCI/AD). Examples include malignant cancer, chemotherapy, HIV, untreated thyroid disease, heart failure, or renal insufficiency * Current diagnosis with diabetes * Illiterate, blind, or non-English speaking * Known periodic antibiotic use (i.e., prior to dental appointments) * Oral PS-specific exclusion criteria: * Inability (e.g., dysphagia) or unwilling to swallow capsules * Active gastrointestinal infection at time of enrollment * Known or suspected toxic megacolon and/or known small bowel ileus * History of total colectomy or bariatric surgery * Concurrent intensive induction chemotherapy, radiation therapy, or biological treatment for active malignancy * Unable or unwilling to comply with protocol requirements * Expected life expectancy less than 6 months * Previous use of probiotic supplementation (PS) or microbiome-based products within 2 months, large doses of commercial probiotics consumed (greater than or equal to 10\^8 cfu or organisms per day). Includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component (ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply). Enrollment after 2 months without probiotic use can be considered for eligibility * Patients with severe anaphylactic or anaphylactoid food allergy * Solid organ transplant recipients less than or equal to 90 days post-transplant or on active treatment for rejection * A condition that would jeopardize the safety or rights of the participant, would make it unlikely for the participant to complete the study, or would confound the results of the study * Exclusionary factors affecting the microbiome: * Previous use of systemic antibiotics (intravenous, intramuscular, or oral) within 3 months (depends on the duration of antibiotic use, i.e., less than 3 months is considered exclusion, however, enrollment after 3 months without antibiotic use can be considered for eligibility) * Immune stimulating and/or suppressing medications * Immunosuppressed as evaluated by complete blood count (CBC) with differential, which includes white blood cell count, total neutrophil count, and total lymphocyte count * Unstable dietary history during the previous month, which is defined as major changes in diet by eliminating or significantly increasing a major food group * Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years * Major bowel resection at any time * Active uncontrolled gastrointestinal disorders or disease including inflammatory bowel disease, ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis; irritable bowel syndrome (moderate-severe); persistent, infectious gastroenteritis, colitis, or gastritis; persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated), or chronic constipation
Where it's running
-
University of Wisconsin Hospitals and Clinics
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Barbara Bendlin, PhD — UW School of Medicine and Public Health
- Study coordinator: Alfred Braceros, BA
- Email: braceros@medicine.wisc.edu
- Phone: 608-263-9485
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.